Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.56 |
| ▸ | HTR6 | P50406 | 4/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.41 |
| ▸ | KHK | P50053 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | QDPR | P09417 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17232840 | 0.83 | HTR2C (0.71) | HTR2CP2RY14SIGMAR1QDPR | |
| Hydrochloric Acid SCHEMBL17222909 | 0.81 | HTR2C (0.72) | HTR2CHTR6P2RY14SIGMAR1QDPR | |
| SCHEMBL15077316 | 0.80 | HTR6 (0.51) | HTR2CHTR6HTR2AKHKSIGMAR1 | |
| SCHEMBL10104504 | 0.76 | HTR2C (0.62) | HTR2CHTR6HTR2AP2RY14SIGMAR1 | |
| SCHEMBL20040946 | 0.76 | HTR2C (0.62) | HTR2CP2RY14SIGMAR1QDPR | |
| SCHEMBL4789631 | 0.75 | HTR2C (0.56) | HTR2CHTR6HTR2AKHKSIGMAR1 | |
| SCHEMBL4789895 | 0.75 | HTR2C (0.57) | HTR2CHTR6HTR2AKHKSIGMAR1 | |
| SCHEMBL794772 | 0.74 | SLC6A4 (0.46) | QDPR | |
| Trifluoroacetic Acid SCHEMBL31227326 | 0.74 | HTR2C (0.53) | HTR2CHTR6HTR2AP2RY14KHK | |
| SCHEMBL15542566 | 0.74 | SCN2A (0.33) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2864289-B1 | CYCLOPROPANECARBOXAMIDO-SUBSTITUTED AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS | CB THERAPEUTICS INC (KY) | 2018-04-11 | — | — | EP | disclosed |
| EP-2864289-B1 | CYCLOPROPANECARBOXAMIDO-SUBSTITUTED AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS | CB THERAPEUTICS INC (KY) | 2018-04-11 | — | — | EP | disclosed |
| US-9840477-B2 | Cyclopropanecarboxamido-substituted aromatic compounds as anti-tumor agents | CB THERAPEUTICS INC. (KY) | 2017-12-12 | — | — | US | disclosed |
| US-9840477-B2 | Cyclopropanecarboxamido-substituted aromatic compounds as anti-tumor agents | CB THERAPEUTICS INC. (KY) | 2017-12-12 | — | — | US | disclosed |
| US-20160280664-A1 | Cyclopropanecarboxamido-Substituted Aromatic Compounds as Anti-tumor Agents | APOLLOMICS INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280664-A1 | Cyclopropanecarboxamido-Substituted Aromatic Compounds as Anti-tumor Agents | APOLLOMICS INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280664-A1 | Cyclopropanecarboxamido-Substituted Aromatic Compounds as Anti-tumor Agents | APOLLOMICS INC. | 2016-09-29 | — | — | US | disclosed |
| US-9359338-B2 | Cyclopropanecarboxamido-substitute aromatic compounds as anti-tumor agents | CROWN BIOSCIENCE INC. (TAIWAN) (TW) | 2016-06-07 | — | — | US | disclosed |
| US-9359338-B2 | Cyclopropanecarboxamido-substitute aromatic compounds as anti-tumor agents | CROWN BIOSCIENCE INC. (TAIWAN) (TW) | 2016-06-07 | — | — | US | disclosed |
| US-9359338-B2 | Cyclopropanecarboxamido-substitute aromatic compounds as anti-tumor agents | CROWN BIOSCIENCE INC. (TAIWAN) (TW) | 2016-06-07 | — | — | US | disclosed |
| US-20150197511-A1 | CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS | APOLLOMICS INC. | 2015-07-16 | — | — | US | disclosed |
| US-20150197511-A1 | CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS | APOLLOMICS INC. | 2015-07-16 | — | — | US | disclosed |
| EP-2864289-A1 | CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS | Crown Bioscience Inc. (Taiwan) (CN) | 2015-04-29 | — | — | EP | disclosed |
| CN-103508961-A | Antitumor drug | CROWN BIOSCIENCE TAICANG CO LTD | 2014-01-15 | — | — | CN | disclosed |
| WO-2014000418-A1 | CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS | CROWN BIOSCIENCE INC. (TAICANG) (CN) | 2014-01-03 | — | — | WO | disclosed |
| EP-2616443-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | Exelixis, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| WO-2012037132-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037132-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280664-A1 | Cyclopropanecarboxamido-Substituted Aromatic Compounds as Anti-tumor Agents | BRAF, RAF1, ARAF | HTR2C 4180/4885HTR6 3880/4885HTR2A 4477/4885 |
| US-20150197511-A1 | CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS | BRAF, ARAF, RAF1 | HTR2C 3888/4885HTR6 3545/4885HTR2A 4291/4885 |
| US-20130165440-A1 | JAK1 Inhibitors | JAK1, JAK2, JAK3 | HTR2C 955/4885HTR6 1155/4885HTR2A 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.